Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2009 Aug;24(8):1525-32.
doi: 10.1007/s00467-009-1138-5. Epub 2009 Mar 12.

Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study

Affiliations
Multicenter Study

Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study

Djalila Mekahli et al. Pediatr Nephrol. 2009 Aug.

Abstract

Long-term outcome of idiopathic steroid-resistant nephrotic syndrome was retrospectively studied in 78 children in eight centers for the past 20 years. Median age at onset was 4.4 years (1.1-15.0 years) and the gender ratio was 1.4. Median follow-up period was 7.7 years (1.0-19.7 years). The disease in 45 patients (58%) was initially not steroid-responsive and in 33 (42%) it was later non-responsive. The main therapeutic strategies included administration of ciclosporine (CsA) alone (n = 29; 37%) and CsA + mycophenolate mofetil (n = 18; 23%). Actuarial patient survival rate after 15 years was 97%. Renal survival rate after 5 years, 10 years and 15 years was 75%, 58% and 53%, respectively. An age at onset of nephrotic syndrome (NS) > 10 years was the only independent predictor of end-stage renal disease (ESRD) in a multivariate analysis using a Cox regression model (P < 0.001). Twenty patients (26%) received transplants; ten showed recurrence of the NS: seven within 2 days, one within 2 weeks, and two within 3-5 months. Seven patients lost their grafts, four from recurrence. Owing to better management, kidney survival in idiopathic steroid-resistant nephrotic syndrome (SRNS) has improved during the past 20 years. Further prospective controlled trials will delineate the potential benefit of new immunosuppressive treatment.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Pediatr. 1994 Dec;125(6 Pt 1):981-6 - PubMed
    1. Pediatr Nephrol. 2006 Jul;21(7):1003-12 - PubMed
    1. Pediatr Nephrol. 2001 Aug;16(8):658-61 - PubMed
    1. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003594 - PubMed
    1. Nephrol Dial Transplant. 1993;8(11):1286-90 - PubMed

Publication types

LinkOut - more resources